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Abstract
Introduction: Biomarker-based cross-sectional incidence estimation requires a Recent Infection Testing Algorithm (RITA)
with an adequately large mean recency duration, to achieve reasonable survey counts, and a low false-recent rate, to
minimise exposure to further bias and imprecision. Estimating these characteristics requires specimens from individuals with
well-known seroconversion dates or confirmed long-standing infection. Specimens with well-known seroconversion dates
are typically rare and precious, presenting a bottleneck in the development of RITAs.
Methods: The mean recency duration and a ‘false-recent rate’ are estimated from data on seroconverting blood donors.
Within an idealised model for the dynamics of false-recent results, blood donor specimens were used to characterise RITAs
by a new method that maximises the likelihood of cohort-level recency classifications, rather than modelling individual
sojourn times in recency.
Results: For a range of assumptions about the false-recent results (0% to 20% of biomarker response curves failing to reach
the threshold distinguishing test-recent and test-non-recent infection), the mean recency duration of the Vironostika-LS
ranged from 154 (95% CI: 96–231) to 274 (95% CI: 234–313) days in the South African donor population (n=282), and from
145 (95% CI: 67–226) to 252 (95% CI: 194–308) days in the American donor population (n=106). The significance of gender
and clade on performance was rejected (p2value=10%), and utility in incidence estimation appeared comparable to that of
a BED-like RITA. Assessment of the Vitros-LS (n=108) suggested potentially high false-recent rates.
Discussion: The new method facilitates RITA characterisation using widely available specimens that were previously
overlooked, at the cost of possible artefacts. While accuracy and precision are insufficient to provide estimates suitable for
incidence surveillance, a low-cost approach for preliminary assessments of new RITAs has been demonstrated. The
Vironostika-LS and Vitros-LS warrant further analysis to provide greater precision of estimates.
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Introduction
Incidence (the rate of new infections) provides a more direct and
current indication of the spread of the Human Immunodeficiency
Virus (HIV) than prevalence (the fraction of the population in an
infected state). Incidence estimates are key to monitoring
epidemics, assessing outbreaks, and targeting and evaluating
interventions. Prospective longitudinal studies, which allow for
the direct counting of new infections in cohorts of individuals, are
costly, logistically difficult to set up and maintain, and prone to
capturing unrepresentative behaviours. Consequently, estimation
of incidence using cross-sectional surveys [1–3] has attracted much
interest over recent years.
Recent Infection Testing Algorithms (RITAs), often referred to
as Serologic Testing Algorithms for Recent HIV Seroconversion
(STARHS) [2], classify infections as recently or non-recently
acquired. Incidence is then related to the prevalence of RITA-
defined recent infection [1–11] as estimated in a cross-sectional
survey.
RITAs traditionally employ the laboratory measurement of
HIV viral or host biomarkers which evolve with time after
infection. Antibody avidity, titre, or HIV-specific proportion is
typically considered, with a measurement below a chosen
threshold indicative of recent infection [12–14].
Immune responses vary for individuals, with each individual
experiencing a unique evolution of the biomarker. There are two
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population-level incidence estimation.
1. The RITA-defined state of recent infection should not be too
transient. This ensures that the proportion of the population in
this state may be estimated with good statistical power in
surveys with feasible sample sizes. Therefore, the average time
spent in the state of recent infection, termed the mean
recency duration, v, should be large (typically, at least six
months [15]).
2. For many RITAs, there is evidence that some long-infected
individuals are classified as recently infected [12,13]. Although
the phenomenon of false-recency may, in principle, be
accounted for without introducing bias, adjustments result in
considerable loss of statistical precision of incidence estimates
[15]. The proportion of long-standing infections classified by
the RITA as recent, termed the false-recent rate, e, should
therefore be as low as feasible.
Increasing the threshold (the biomarker cutoff used to discriminate
recent from non-recent infection) increases the mean recency
duration, but generally also results in a higher false-recent rate.
Therefore, as the threshold varies, there is a trade-off between the
two performance characteristics. Since population-level surveil-
lance is of interest, rather than each individual’s diagnosis, a
sensitivity-specificity trade-off (with recent infection defined by a
fixed duration) is not an appropriate threshold optimisation
criterion (Kassanjee et al, working paper, 2011).
Both calibration data and cross-sectional survey data are
required to estimate incidence. Calibration data is used to estimate
the RITA characteristics, namely the mean recency duration, v,
and false-recent rate, e. Cross-sectional data is used to estimate the
proportions of recently infected, non-recently infected and healthy
individuals in the population, denoted by PR, PNR and PH
respectively.
The incidence estimator, relating the population proportions
and RITA characteristics to incidence, I,i s
I~
PR{
e
1{e
PNR
vPH
: ð1Þ
This has been derived in an analysis by McWalter and Welte
[8], shown to be the maximum likelihood estimator by Wang and
Lagokos [9], and generalised by Welte et al [15]. See McWalter
and Welte [16] for a comparison of this estimator to the previously
proposed estimators of McDougal et al [5] and Hargrove et al [6].
Ideally, the RITA should perform similarly in a number of
populations, allowing for the reuse of RITA characteristic
estimates. However, differences in the stage of the epidemic, or
viral subtype or clade, may necessitate the estimation of these
critical parameters in relevant populations for each study. For
example, the proportions of individuals who are elite controllers
(whose immune systems successfully suppress viraemia in the
absence of treatment), have advanced immunodeficiency or are
receiving antiretroviral therapy may vary, and these individuals
have a propensity to produce false-recent classifications [12,13].
Traditionally, methods of estimating the mean recency duration
have relied on the testing of serial samples from acutely infected
subjects [1–6,9,13,17]. This typically requires at least one pre-
seroconversion and multiple post-seroconversion samples, with
short intervals between follow-up so that the seroconversion and
threshold-crossing times may be estimated with minimal uncer-
tainty. Such panels of data are costly and difficult to capture,
requiring precisely the demanding longitudinal studies that cross-
sectional incidence estimation seeks to circumvent.
Despite being more easily obtained, specimens from serocon-
verting subjects with relatively long intervals between follow-up
have been largely overlooked. Obtaining such specimens from
repeat blood donors provides unique efficiencies as the collection
of blood for transfusions is ongoing in most countries, and
therefore procuring specimens does not require the establishment
of new surveillance. Although the prevalence and incidence of
HIV are generally lower in blood donors than the general
population, the large-scale collection of blood and routine testing
of serial donations for HIV (RNA and antibodies) provide a
relatively large sample of seroconverting donors. Furthermore,
large volumes of plasma, derived from routinely prepared frozen
plasma components, are obtained.
In this investigation, data captured on seroconverting blood
donors in South Africa and the USA is used to demonstrate the
characterisation and optimisation of RITAs.
Methods
Ethics Statement
The research and the incidence testing were approved by the
University of California, San Francisco (UCSF); American Red Cross
(ARC) and South African National Blood Service (SANBS) institutional
review boards or ethics committees.
Specimen Collection and RITA Testing
Specimens were collected by the South African National Blood
Service (SANBS) of South Africa and the American Red Cross (ARC) of
the USA, and tested by the Blood Systems Research Institute (BSRI) of
the USA. Repeat donors who were observed to seroconvert were
tested (by the RITA) using the specimens collected at the times of
the first seropositive donations.
The investigation was performed for the less-sensitive Vironos-
tika assay (Vironostika-LS) [18], the RITA for which more data is
available, and thereafter, the currently-used less-sensitive Vitros
assay (Vitros-LS) [19] was characterised. These RITAs are both
based on ‘less-sensitive’ versions of diagnostic tests that measure
antibody titre, a concept introduced by Janssen et al [2]. For each
RITA, recent infection is indicated by a standardized optical
density (SOD) below a chosen threshold.
The Vironostika-LS is a modification of the Vironostika HIV-1
microELISA diagnostic test (bioMe ´rieux, Marcy l’E ´toile, France)
[18]. The laboratory procedures and threshold of 1 specified by
Rawal et al [18] were used. Seroconverting blood donors were
tested using the Vironostika-LS until 2007, as production of the
Vironostika assay ceased in the year thereafter [13]. Manufactur-
ing of the assay has since been resumed by Avioq (Rockville, MD)
[20].
The Vitros-LS is based on the Ortho Vitros ECi anti-HIV 1+2
instrument (Ortho-Clinical Diagnostics, Raritan, NJ) [19]. The
BSRI established the laboratory conditions that result in the closest
agreement to classifications by the Vironostika-LS, using a
threshold of 20 [19].
The datasets consist of the SOD at the time of the first
seropositive donation, and the interval between the last seroneg-
ative (and RNA negative) and first seropositive donation, termed
the inter-donation (ID) interval, for each seroconverting blood
donor. Three datasets (Supplemental Digital Content (SDC) S1,
Section A) were used for the analysis: The Vironostika-LS was
applied to samples of South African donors (October 2005 -
September 2007, sample size of n=485) and North American
Recency Test Characteristics in Blood Donors
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was applied to a sample of South African donors (October 2007 –
December 2009, n=199).
Analysis
RITA characteristics were estimated using a maximum
likelihood method. Rather than fitting a curve describing the
evolution of the SOD with time after seroconversion, the overall
probability of the RITA classifications at the first seropositive
donations in the sample was maximized [21]. The likelihood
function is derived below (more detail provided in SDC S1,
Section B).
Assuming that the time of seroconversion is uniformly
distributed in the ID interval, the probability, pi, that the i
th
seroconverter, with ID interval Di, is classified as recently infected
at the time of the first seropositive donation is
pi~
Ð Di
0 SR(t)dt
Di
, ð2Þ
where SR(t) is the probability of being in the RITA-defined state of
recent infection when tested a time t after seroconversion.
The likelihood, L, to be maximised, of all RITA classifications in
a sample of n seroconverters is
L ~ P
n
i~1
(pi)
xi(1{pi)
1{xi , ð3Þ
where xi={1 if RITA-recent, 0 if RITA-non-recent} is the
observed result for the i
th seroconverter.
The analyses of McDougal et al [5], McWalter and Welte [8]
and Wang and Lagakos [9] assume that individual SOD curves
either cross the threshold (distinguishing test-recent from test-non-
recent infection) and remain above it or fail to ever reach the
threshold, and therefore SR(t) in (2) approaches some constant
value, a, which is the proportion of SOD curves that fail to reach
the threshold, for large t. SR(t) may then be expressed as
SR(t)~ az(1{a)SR0(t): ð4Þ
The mean recency duration, v, is the mean of the times taken to
cross the threshold for those SOD curves that do cross the
threshold, as described by SR’(t).
Substituting (4) into (2), pi becomes
pi ~az(1{a)
Ð Di
0 SR0(t)dt
Di
: ð5Þ
This approach also facilitates non-parametric inference, by
considering only individuals with large Di. For a time cutoff T
such that
SR0(t) ~0 i:e: SR(t)~ a ðÞ V twT ð6Þ
if Di.T, then
ðDi
0
SR0(t)dt~
ð?
0
SR0(t)dt~ v ð7Þ
is the mean recency duration.
Substituting (7) into (5), pi becomes a function of the RITA
characteristics,
pi ~ az(1{a)
v
Di
,8 ðÞ ð 8Þ
and no assumptions about the shape with which the biomarker
grows after seroconversion (full characterisation of SR’(t))i s
required. The estimated RITA characteristics maximise the
likelihood L, which is now a function of v, and a (if there is no
input estimate of a).
McDougal et al [5], McWalter and Welte [8] and Wang and
Lagakos [9] additionally assume that post-seroconversion survival
is independent of the shape of the SOD curves. When the above-
mentioned assumptions are obeyed, a=e in the incidence
estimator (1). More generally, SR(t) may not remain constant for
t.T. A false-recent rate may then be defined as the proportion of
individuals, seropositive for longer than T, that is classified as
recently infected [15]. In this case, the above procedure that
produces an estimate of a likely overestimates the false-recent rate
if SOD curves cross the threshold after T or underestimates it if
SOD curves move back below the threshold at times since
seroconversion greater than that captured in the dataset. The
estimated RITA characteristics, a and v, therefore provide
unrefined estimates for the false-recent rate and mean recency
duration.
Uniformly distributed seroconversion times are reasonable
when the timing of donations and exposures to HIV are
independent. Test-seeking behaviour (the donation of blood soon
after exposure specifically to receive HIV testing) or deferral of
donations (the delay of donations soon after exposure) could
therefore bias estimates. In the USA, an investigation, which
highlighted test-seeking behaviour among homosexual men, noted
little indication of test-seeking behaviour among blood donors
[22], while evidence of deferred donations has been observed [23].
Behaviour in the South African donor population may vary due to
the large scale of the epidemic and stigma associated with HIV.
In this work, various analyses involving the parametric and non-
parametric inference of the RITA characteristics for the
Vironostika-LS and Vitros-LS were performed. Parametric
inference was performed by maximising the likelihood function
based on the probability of being recently infected expressed in (5),
assuming forms for SR’(t) and using all data; non-parametric
inference was performed using a likelihood function based on (8)
and only including data satisfying Di.T. Using simulated data,
estimates obtained from the parametric and non-parametric
approaches were compared. Differences in RITA characteristics
for specific subpopulations were explored. The utility of the RITA
for obtaining precise incidence estimates was also investigated.
Asymptotic maximum likelihood theory was used to estimate
confidence intervals (CIs) and confidence regions (CRs), and test
the significance of parameters (based on the distribution of the
deviance statistic and using the loglikelihood ratio test) [24]. Chi-
squared goodness of fit tests were used to assess the agreement
between data and assumptions [25]. All tests used a significance
level of 5%.
Results
Characterisation of the Vironostika-LS
The estimated RITA characteristics (using a threshold of 1) are
shown (Fig. 1), for both estimation assuming a known a, and
simultaneous estimation of v and a. Observations with Di.T=1
Recency Test Characteristics in Blood Donors
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been estimated to be 200 days [26] and 1 year [17]), resulting in
sample sizes of n=282 and n=106 for the South African and
American datasets respectively. A comparison of the observed
percentages of seroconverters who were recently infected to the
expected percentages (by substituting the estimated RITA
characteristics into (8)), as functions of ID interval, suggests good
agreement under simultaneous estimation of the RITA charac-
teristics (SDC S1, Section C). When exploring the sensitivity of
results to T, when T was increased to 2.5 years, estimates from the
South African dataset varied by at most 10% (n=189), while the
large uncertainty in estimates from the relatively small American
dataset (n=53) did not support meaningful inference.
The estimated a is large, consistent with the results from the
application of this method to assess the BED assay [21(results not
shown)]. Estimation of v using an input estimate of a is preferable.
In the extreme case of all ID intervals being equal, v and a cannot
be simultaneously estimated as the likelihood function may be kept
at its maximum while arbitrarily increasing the estimate of v by
appropriately decreasing the estimate of a. Furthermore, using a
value of T that is too low (SOD curves cross the threshold after T)
would bias estimates of a upwards and v downwards under the
assumptions of McDougal et al [5], McWalter and Welte [8] and
Wang and Lagakos [9], with larger T required at higher
thresholds.
The estimated mean recency durations, for a number of
thresholds (holding T at 1 year), are compared to published
estimates (Fig. 2):
1. Busch et al [27] utilised the directly measured incidence in the
repeat donor population to estimate v. With known incidence;
proportions PR, PNR and PH (determined by testing repeat
donors); and assuming e=0%; a ‘back-calculation’ for v using
the incidence estimator was performed. Since the possibility of
false-recent results was neglected, overestimation of v is
expected, with greater bias at higher thresholds. Methodolog-
ically, estimation of v by ‘back-calculation’ requires an existing
estimate of e for the same threshold, with such data currently
unavailable. Furthermore, uncertainty in the estimate of v
Figure 1. Estimated RITA characteristics for the Vironostika-LS
in the repeat donor population. The estimates of the mean recency
duration, v, under both the simultaneous estimation of v and a, and
when using an input a, for T=1 year, are provided. For the latter
estimation, the estimated v is plotted as a function of the assumed a.
The 95% confidence regions (CRs) for v and a (simultaneous
estimation) and confidence intervals (CIs) for v (assuming a, and not
accounting for uncertainty in a) are displayed. Part A shows the results
for the South African repeat donor sample, while Part B shows the
results for the USA repeat donor sample.
doi:10.1371/journal.pone.0020027.g001
Figure 2. Comparison of mean recency duration estimates for
the Vironostika-LS to previously published estimates. Estimates
of the mean recency duration, v, under both the simultaneous
estimation of v and a, and when assuming a=0%, for T=1 year, are
compared to published estimates (by ‘back-calculation’ in the repeat
donor population [27] and using seroconversion panels [18,27]) as a
function of test threshold. The minimum and maximum v occurring in
the 95% confidence regions (CRs) for v and a (simultaneous
estimation), as well as 95% confidence interval (CI) limits for v
(assuming a=0%, with no uncertainty) are also displayed. Estimates
shown in Part A pertain to the South African population, while those in
Part B pertain to the USA population.
doi:10.1371/journal.pone.0020027.g002
Recency Test Characteristics in Blood Donors
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PR, PNR and PH; and e.
2. The Centers for Disease Control and Prevention (CDC) utilised
seroconversion panels to estimate v in an American population
[18,27].
Parametric versus non-parametric approach
The need for parametric assumptions about the shape of the
antibody titre response curve is circumvented by using only data
with large ID intervals. This has two consequences:
1. Estimation of v is less prone to bias arising from poor
parametric assumptions.
2. The dataset used for the estimation is reduced in size,
decreasing the precision (increasing the variability) of estimates
of v.
The characterisation of the Vironostika-LS in the South African
repeat donor population was revisited, using all data. The
probability that a seroconverter is recently infected at the first
seropositive donation is given by (5), which assumes a parametric
form for SR’(t).
For SR’(t)=SR’(h,t), where h is a vector of parameters, the
maximum likelihood estimator of v is
^ v v~
ð?
0
SR0(^ h h,t)dt, ð9Þ
where h is estimated to maximise the likelihood function.
A number of forms for SR’(t) were assumed, ranging from a fixed
recency duration for all individuals, to a fat-tailed Pareto
distribution (for the time spent in the state of recency). Widely
varying estimates of v (SDC S1, Section D) were obtained, even
after excluding estimates for which assumptions and data poorly
agreed. Since the true underlying dynamics of the data are
unknown, the extent of bias is unclear.
Simulated data was therefore used to explore the trade-off
between greater precision from larger samples and greater
potential for bias from poor parametric assumptions, when using
all data. Assuming a number of forms for SR’(t), 100 datasets (of
500 seroconverters each) were simulated. For each dataset, v was
estimated using a number of parametric assumptions. The results
of the investigation (SDC S1, Section D) suggest that power to
reject ‘incorrect’ parametric assumptions is at times poor and large
bias in estimates may occur. When the assumptions leading to (8)
hold, estimates using the non-parametric approach are unbiased,
although less precise.
Despite the reduction in sample size (approximately 40% for
T=1 year) when using the non-parametric method of estimation,
bias arising from indistinguishably poor parametric assumptions is
eliminated, leading to more accurate estimates.
Population-specific performance
Significant systematic bias could be introduced to incidence
estimates if the RITA characteristics are not evaluated in a
population representative of that in which incidence estimation is
to occur [11,15]. Since most HIV antibody assays are based
primarily on clade B antigens, antibody-antigen reactivity may
vary when applying assays in populations in which other clades
occur [28], with differences in the performance of the Vironostika-
LS already observed [18,26,28–30]. Other factors, such as the
association between viral RNA levels and clade, and seroconver-
ters’ genetic backgrounds, may also affect results [4,12,13,28].
The significance of gender (male and female) and country
(South Africa and USA) on the performance of the Vironostika-LS
was assessed. Country differences are likely to be largely
representative of clade differences, as clade C infections are
predominant in South Africa, and clade B in the USA [31].
Investigations by SANBS on a sample of donors (data made
available to authors) and studies of North American donors
[32,33] indicate that a very small percentage (,5%) of infections
are not of the predominant clade.
The null hypothesis, that the performance of the Vironostika-
LS is common in all four groups (each pairing of gender and
country), is not rejected with a p-value of 10.48% (estimated
RITA characteristics in Fig. 3). However, in this investigation,
large uncertainty in estimates, arising from small samples of
seroconverters, would result in little power to identify significant
factors.
Optimisation of RITA design and comparison of RITAs
The ultimate objective is incidence estimation. The precision of
the incidence estimator (and hence power to detect changes in
incidence) increases with a larger mean recency duration and
smaller false-recent rate [15]. However, there is a fundamental
trade-off between these RITA characteristics as both parameters
Figure 3. Estimated RITA characteristics for the Vironostika-LS
in the repeat donor population by gender and country.
Estimates of v and a, under the simultaneous estimation of these
parameters, are shown for South African male donors, South African
female donors, USA male donors and USA female donors. 95%
confidence regions (CRs) for v and a are provided.
doi:10.1371/journal.pone.0020027.g003
Recency Test Characteristics in Blood Donors
PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e20027increase with increasing threshold, shown for the Vironostika-LS,
South Africa (Fig. 4A and Fig. 4B, a provides an indication of the
magnitude of the false-recent rate).
The coefficient of variation (CoV, ratio of standard deviation
to mean) of the incidence estimator [8], given the estimated
performance of the Vironostika-LS, is compared to that
achieved by a BED-like RITA (v=d a y sa n de =5.6%, as
per BED package insert [34]), assuming e=a (Fig. 4C). HIV
incidence of 1.5% and prevalence of 17.5% are assumed, based
on the South African adult population [35,36]. With the CoV
ratio (Vironostika-LS to BED-like) indistinguishable from 1, at
all thresholds considered, the Vironostika-LS appears compara-
ble to a BED-like RITA. Additional data, such as captured
during the follow-up of seropositive individuals awaiting
treatment, could be used to explore whether systematic artefacts
in the estimation occur (for example, from individuals progress-
ing after T=1 year).
Characterisation of the Vitros-LS
Preliminary RITA characteristic estimates of the currently used
Vitros-LS (using a threshold of 20), for the South African repeat
donor population, are shown (Fig. 5). The simultaneous estimation
of v and a, for a range of T, was performed (n=108 for T=1 year
reduces to n=59 for T=2.5 years). Observed and expected
percentages of seroconverters who were recently infected were also
compared (SDC S1, Section E).
Figure 4. Performance of the Vironostika-LS for incidence estimation, based on estimated RITA characteristics. The estimated
performance of the Vironostika-LS, for incidence estimation purposes, is shown, based on estimated RITA characteristics for the South African repeat
donor population. In Part A and Part B, estimates of v and a, respectively, under the simultaneous estimation of these parameters, for T=1 year, are
plotted as a function of test threshold. The minimum and maximum v and a occurring in the 95% confidence regions (CRs) for these parameters are
also displayed. In Part C, the estimated precision of the incidence estimator using the Vironostika-LS is compared to the precision obtained by a BED-
like RITA (v=155 days and e=5.6% [34]), based on the estimated RITA characteristics (assuming e=a) and assuming constant HIV incidence of 1.5%
and prevalence of 17.5%. More specifically, the ratio of the coefficient of variation (CoV, ratio of standard deviation to mean) of the incidence
estimator, for the Vironostika-LS to the BED-like RITA, is plotted as a function of the Vironostika-LS test threshold. *A polynomial is fitted by least
squares to smooth estimates.
doi:10.1371/journal.pone.0020027.g004
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function of cutoff time T (Fig. 5) as no estimates for T were found
in the literature and the estimation appeared fairly sensitive to the
choice of T for this dataset. The widely varying estimates for the
RITA characteristics, and large uncertainty around them, indicate
the need for a larger dataset and an external estimate of a for a
carefully selected cutoff time T (large enough for the SOD curves
to cross the threshold) to get a more accurate and precise estimate
of the mean recency duration. Such data and estimates of a and T
are currently unavailable. While a value of T that is too small
would bias estimates of a upwards and v downwards, under the
above-mentioned assumptions, as the value of T increases, the
sample size reduces and interdonation intervals are more closely
clustered together, decreasing the power to perform simultaneous
estimation.
The large, albeit highly uncertain, estimates of a suggest that
one should be cautious about the utility of the Vitros-LS in
incidence estimation at this stage of the characterisation, noting
that a is not the false-recent rate in (1) for SR(t) not (approximately)
constant for t.T.
Discussion
Traditionally, the characterisation of RITAs (individual assays
and multiple-test algorithms) has relied on the use of serocon-
version panels. The scarcity of these panels is therefore an
obstacle to the development of RITAs for incidence estimation.
In this work, a source of more readily available specimens has
been identified, and an approach for obtaining preliminary
characterisations of RITAs using these specimens has been
demonstrated. Further refinement of the characterisation of only
the most promising RITAs may thereafter be performed, thus
conserving precious longitudinal specimens (and specimens from
populations with long-standing infections) for this purpose.
Utilising specimens from blood donors provides unique
efficiencies as relatively large samples of seroconverters and
high-volume specimens (125-250 ml of plasma per seroconverter)
are captured during routine blood collection procedures. Further-
more, specimens from seropositive individuals around the world
are collected, facilitating tests for population-specific performance
differences of a RITA.
The method of estimating the RITA characteristics (mean
recency duration and a proxy ‘false-recent rate’ for parameter
estimation purposes) does not require the follow-up of serocon-
verters. Moreover, by using data with large (pre-seroconversion)
follow-up intervals, non-parametric estimation is supported. To
obtain more accurate and precise estimates of the mean recency
duration, an external estimate of the proportion of SOD curves
that does not reach the threshold is desirable, as well as insight into
the maximum time seroconverters spend in the test-recent state.
For incidence estimation, the utility of the Vironostika-LS
appears comparable to a BED-like RITA, over the range of
thresholds considered. The precision of the incidence estimator
provides a criterion for both comparing RITAs as well as
identifying optimal thresholds. While additional data is required
for the Vitros-LS, preliminary results suggest prudence when
utilising the assay for incidence estimation.
The assumptions under which estimates are unbiased are strict.
Potential for systematic bias in estimates, such as that arising from
individuals remaining in the state of recency for prolonged periods,
or from non-uniformly distributed seroconversion times, should be
explored using additional data. This method of estimating the
RITA characteristics is not intended to provide final parameter
estimates required for incidence estimation, but rather for
providing cost-effective and efficient preliminary assessments of
RITAs. It is hoped that the concepts and tools demonstrated in
this work will contribute to the resourceful characterisation, and
subsequently focused development, of RITAs for population-level
incidence estimation.
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Figure 5. Estimated RITA characteristics for the Vitros-LS in the
South African repeat donor population. The estimates of the RITA
characteristics, v and a, under the simultaneous estimation of the
parameters are provided, as a function of the cutoff time T, for T=1 year
to T=2.5 years. In Part A and Part B, estimates of v and a are plotted,
respectively. The minimum and maximum v and a occurring in the 95%
confidence regions (CRs) for these parameters are also displayed. *A
polynomial is fitted by least squares to smooth estimates.
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